ScholarLens Back to search
2017•PubMedRequires access

Greater Benefit with Rivaroxaban Than Aspirin for Extended Treatment of VTE.

Allen F. Shaughnessy

Open publisher page 5 citations

Abstract

Compared with aspirin, the use of rivaroxaban (Xarelto) to extend anticoagulation beyond the initial six to 12 months to treat provoked or unprovoked VTE reduces the risk of recurrent symptomatic VTE without increasing the risk of bleeding. You would need to treat approximately 30 to 33 patients with full- or low-dose rivaroxaban to prevent one additional clot.

About this research paper

What this paper is about

Compared with aspirin, the use of rivaroxaban (Xarelto) to extend anticoagulation beyond the initial six to 12 months to treat provoked or unprovoked VTE reduces the risk of recurrent symptomatic VTE without increasing the risk of bleeding. You would need to treat approximately 30 to 33 patients with full- or low-dose rivaroxaban to prevent one additional clot.

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Compared with aspirin, the use of rivaroxaban (Xarelto) to extend anticoagulation beyond the initial six to 12 months to treat provoked or unprovoked VTE reduces the risk of recurrent symptomatic VTE without increasing the risk of bleeding. You would need to treat approximately 30 to 33 patients with full- or low-dose rivaroxaban to prevent one additional clot.

Key concepts: Medicine, Rivaroxaban, Aspirin, Lung cancer, Internal medicine, Lung, Intensive care medicine, Warfarin

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Greater Benefit with Rivaroxaban Than Aspirin for Extended Treatment of VTE. — Research Paper | ScholarLens